Ken Griffin Cytek Biosciences, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 400 shares of CTKB stock, worth $2,728. This represents 0.0% of its overall portfolio holdings.
Number of Shares
400
Previous 200
100.0%
Holding current value
$2,728
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CTKB
# of Institutions
133Shares Held
71.6MCall Options Held
400Put Options Held
0-
Black Rock Inc. New York, NY17.1MShares$116 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$80.3 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD9.49MShares$64.7 Million1.15% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$45.4 Million0.85% of portfolio
-
State Street Corp Boston, MA4.17MShares$28.4 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $918M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...